3/31/2023  2:10:25 PM Chg. +9.00 Volume Bid2:11:35 PM Ask2:11:35 PM Market Capitalization Dividend Y. P/E Ratio
1,112.50GBX +0.82% 128,555
Turnover(GBP): 1.43 mill.
1,113.50Bid Size: 73 1,114.00Ask Size: 541 9.02 bill.GBP - -

Business description

Smith & Nephew plc is a global medical technology business. The company has two reportable business segments: Advanced Surgical Devices (Orthopaedic Reconstruction, Trauma & Extremities, Sports Medicine and Arthroscopy Enabling Technologies) and Advanced Wound Management. Smith & Nephew has a track record of bringing innovative new products to market that provide better clinical outcomes for patients and save costs for healthcare providers. The company has distribution channels, purchasing agents and buying entities in over 100 countries worldwide. Smith & Nephew plc is headquartered in London, UK.
 

Management board & Supervisory board

CEO
Roland Diggelmann
Management board
Anne-Françoise Nesmes, Brad Cannon, Catheryn O'Rourke, Elga Lohler, Mark Gladwell, Melissa Guerdan, Myra Eskes, Peter Coenen, Phil Cowdy, Simon Fraser, Skip Kiil, Susan Swabey, Vasant Padmanabhan
Supervisory board
Angie Risley, Anne-Françoise Nesmes, Bob White, Erik Engstrom, John Ma, Katarzyna Mazur-Hofsaess, Marc Owen, Rick Medlock, Roberto Quarta, Robin Freestone, Roland Diggelmann, Susan Swabey
 

Company data

Name: Smith & Nephew plc
Address: 15 Adam Street,UK-London WC2N 6LA
Phone: +44-20-7401-7646
Fax: +44-20-7960-2358
E-mail: -
Internet: www.smith-nephew.com/
Industry: Healthcare
Sector: Medical Products
Sub sector: Advanced Medical Devices
End of financial year: 12/31
Free Float: 94.80%
IPO date: -

Investor relations

Name: Andrew Swift
IR phone: +44-20-7960-2285
IR Fax: -
IR e-mail: -

Company calendar

CW 17 | 4/26/2023 Interim Report 1st Quarter/3 Months
CW 31 | 8/3/2023 Interim Report 2nd Quarter/6 Months
CW 44 | 11/2/2023 Interim Report 3rd Quarter/9 Months
 

Main Shareholders

Freefloat
 
94.80%
BlackRock, Inc.
 
5.20%